Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 16/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204430 | 0.93 | MMP13 (0.72) | MMP13 | |
| SCHEMBL6201898 | 0.86 | MMP13 (0.61) | MMP13MMP2MMP9 | |
| SCHEMBL6201793 | 0.86 | MMP13 (0.66) | MMP13 | |
| SCHEMBL6204843 | 0.85 | MMP13 (0.73) | MMP13 | |
| SCHEMBL6332203 | 0.84 | MMP13 (0.77) | MMP13MMP2MMP9 | |
| SCHEMBL6205098 | 0.84 | MMP13 (0.77) | MMP13 | |
| SCHEMBL6203520 | 0.84 | MMP13 (0.63) | MMP13 | |
| SCHEMBL6203703 | 0.84 | MMP13 (0.63) | MMP13 | |
| SCHEMBL6204344 | 0.84 | MMP13 (0.66) | MMP13MMP2MMP9 | |
| SCHEMBL6204474 | 0.84 | MMP13 (0.63) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501834-B1 | TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6916807-B2 | Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1503761-A1 | SUBSTITUTED PIPERAZINES AS MELANOCORTIN RECEPTOR LIGANDS | Neurocrine Biosciences, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20030225056-A1 | Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003094918-A1 | SUBSTITUTED PIPERAZINE AS MELANOCORTIN RECEPTORS LIGANDS | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225056-A1 | Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP8 | MMP13 15/4885HRH3 3881/4885MMP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.